Loading...
Eribulin treatment for patients with metastatic breast cancer: The United Kingdom experience-a multicenter retrospective study
Jafri, M. Kristeleit, H. Misra, V. Baxter, M. Ahmed, S. Jegannathen, A. Jain, A. Maskell, D. Barthakur, U. Edwards, G.
Jafri, M.
Kristeleit, H.
Misra, V.
Baxter, M.
Ahmed, S.
Jegannathen, A.
Jain, A.
Maskell, D.
Barthakur, U.
Edwards, G.
Citations
Altmetric:
Abstract
Purpose: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK.
Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS).
Results: Among 577 patients analyzed, the median age was 56 years and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315) and the PFS was 117 days (95% CI: 105-129). Median OS was higher among older patients (≥ 65 vs < 65 years: 325 days [95% CI: 264-385] vs 285 days [95% CI: 252-317]; P = 0.028). Median OS was also higher in patients that received eribulin after fewer prior lines of chemotherapy (≤ 2 vs > 2 prior: 328 days [95% CI: 264-385] vs 264 days [95% CI: 229-298]; P = 0.042).
Conclusions: These retrospective data suggest eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings which, while predictable, supports consideration of eribulin as a second-line treatment option.
Description
Date
2022
Publisher
Collections
Files
Keywords
Type
Article
Citation
Jafri M, Kristeleit H, Misra V, Baxter M, Ahmed S, Jegannathen A, et al. Eribulin treatment for patients with metastatic breast cancer: The United Kingdom experience-a multicenter retrospective study. Oncology. PubMed PMID: WOS:000848465400001.